Tratamiento endovascular del síndrome de vena cava superiorNuestra experiencia clínica en la última década
- Merino Díaz, Borja
- Brizuela, J. A.
- Mengíbar Fuentes, Lucas
- Salvador Calvo, R.
- Revilla Calavia, Alvaro
- González Fajardo, J. A.
- Vaquero Puerta, Carlos
ISSN: 1139-8264
Year of publication: 2010
Volume: 13
Issue: 1
Pages: 17-20
Type: Article
More publications in: Revista española de investigaciones quirúrgicas
Abstract
INTRODUCTION. The superior vena cava syndrome (SVCS) is caused by a difficulty of the venous return mainly due to malignant tumors, with less frequent benign (pacemakers, catheters permanent ...). OBJECTIVE. We reviewed our experience in endovascular treatment of this syndrome and its therapeutic management. PATIENTS AND METHODS. Between 1998 and 2008 were a total of 13 endovascular procedures (PTA and Stent self) in patients with SVCS, 10 (77%) of whom were men and 3 (23%) females, mean age 63.45 years. The etiology was in 6 cases of carcinoma of the lung (46.2%), 1 case of esophageal carcinoma (7.6%), 3 metastases in the mediastinum (23.1%) and 3 in the presence of central route to treatment with chemotherapy (23.1%). RESULTS. The endovascular procedure was optimal in 12 cases, stent migration occurred in 1 case. The approach was femoral in 10 cases (77%) and chest circumference in 3 (23%). 11 patients (84.6%) were operated under local anesthesia and 2 (15.4%) with their general systemic problems. No patient died in relation to the intervention. Clinical improvement was immediate. 2 recurrences (15.4%) were observed and treated with angioplasty. During follow-up to 10 years, 7 patients died of progression of their disease. CONCLUSIONS. Endovascular treatment of SVCS is a safe and effective procedure that provides a rapid improvement in quality of life and compressive symptoms. The optimal anticoagulation regime must be defined.